Skip to Main Content

Paper Details

Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Invest New Drugs
6
2021
Author NameAffiliation
Susan M PerkinsIndiana University School of Medicine
David I QuinnUniversity of Southern California Norris Comprehensive Cancer Center
  • 1 - 2

Datasets

Release 1.2